

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

July 31, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Sub.: Outcome of Board Meeting held today i.e. Friday, July 31, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

Dear Sir/ Ma'am,

With reference to the intimation of Board meeting submitted on July 28, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, July 31, 2026, on review and recommendation of Audit Committee of the Company, has inter-alia considered and approved, the unaudited Standalone and Consolidated Financial Results for the first quarter ended on June 30, 2026.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the unaudited Standalone and Consolidated Financial Results of the Company for the first quarter ended on June 30, 2026, along with the Limited Review Report issued by M/s. BSR & Co. LLP, the Statutory Auditors.

The Board Meeting commenced at 03:30 P.M. and concluded at 4:35 P.M.

This is for your information and records.

For Concord Biotech Limited

Paritosh Trivedi
Company Secretary and Compliance Officer
ACS 63623


Encl : As above

Limited Review Report on unaudited consolidated financial results of Concord Biotech Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Concord Biotech Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Concord Biotech Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited Review Report (Continued)

Concord Biotech Limited

7. We did not review the interim financial information of two Subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 26.86 Lakhs, total net loss after tax (before consolidation adjustments) of Rs. 7.69 Lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 7.69 Lakhs, for the quarter ended 30 June 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of one Subsidiary which has not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. 7.59 Lakhs, total net loss after tax (before consolidation adjustments) of Rs. 331.73 Lakhs and total comprehensive loss (before consolidation adjustments) of Rs. 330.86 Lakhs, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 6.26 Lakhs and total comprehensive income of Rs. 6.26 Lakhs, for the quarter ended 30 June 2026 as considered in the Statement, in respect of one joint venture, based on its interim financial information which has not been reviewed. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248WW-100022

Rupen Shah

Partner

Ahmedabad

31 July 2026

Membership No.: 116240

UDIN:26116240QVVBRN1915

Limited Review Report (Continued)
Concord Biotech Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Concord Biotech Limited	Parent Company
2	Concord Lifegen Limited	Wholly owned subsidiary
3	Celliimmune Biotech Private Limited	Wholly owned subsidiary
4	Stellon Biotech Inc.	Subsidiary
5	Concord Biotech Japan K.K.	Joint Venture



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440



E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED JUNE 30, 2026

(Rs. In lakhs except per share data)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 2)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
1	Income				
a	Revenue from operations	25,748.90	32,607.96	20,398.76	1,05,489.07
b	Other income	1,282.59	1,534.94	1,367.76	5,235.53
	Total Income	27,031.49	34,142.90	21,766.52	1,10,724.60
2	Expenses				
a	Cost of materials consumed	6,985.45	7,054.09	5,990.99	25,434.78
b	Purchase of stock-in-trade	1,129.00	1,567.02	1,284.63	6,260.63
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,685.35)	(39.62)	(2,765.10)	(7,128.30)
d	Employee benefits expense	4,363.81	4,777.12	3,789.74	17,690.48
e	Finance costs	3.64	8.40	5.86	28.32
f	Depreciation and amortisation expense	1,809.95	1,954.39	1,777.63	7,445.86
g	Other expenses				
	Power and fuel	3,472.01	2,975.97	2,947.50	11,619.93
	Others	4,246.40	4,420.23	3,011.32	14,871.56
	Total Expenses	19,324.91	22,717.60	16,042.57	76,223.26
3	Profit before exceptional items and tax (1-2)	7,706.58	11,425.30	5,723.95	34,501.34
4	Exceptional items:				
	Statutory impact of new labour codes (refer note 3)	-	-	-	327.54
5	Profit before tax and share of profit of joint venture (3-4)	7,706.58	11,425.30	5,723.95	34,173.80
6	Share of profit / (loss) of joint venture (net of tax)	127.73	(17.76)	149.23	290.92
7	Profit before tax (5+6)	7,834.31	11,407.54	5,873.18	34,464.72
8	Tax expenses:				
a	Current tax	2,036.59	2,864.81	1,407.85	8,629.09
b	Deferred tax	28.03	(303.96)	59.55	(87.28)
	Total tax expenses	2,064.62	2,560.85	1,467.40	8,541.81
9	Profit after tax for the period/year (7-8)	5,769.69	8,846.69	4,405.78	25,922.91
10	Other comprehensive income (net of tax)				
	Items that will not be reclassified to profit or loss				
a	Re-measurement gain/ (loss) on defined benefit plans	71.56	(68.75)	(32.07)	(162.24)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	(18.01)	17.30	8.07	40.83
c	Fair value changes on equity investments through OCI	1,927.33	1,685.42	(344.61)	6,687.09
d	Income tax relating to fair value changes on equity investments through OCI	(275.61)	(272.63)	86.73	(987.87)
	Items that will be reclassified to profit or loss				
e	Foreign currency translation reserves	0.87	(35.01)	-	(53.45)
	Other comprehensive income for the period/year	1,706.14	1,326.33	(281.88)	5,524.36
11	Total comprehensive income for the period/year(9+10)	7,475.83	10,173.02	4,123.90	31,447.27
12	Profit for the period attributable to:				
	Owners of the company	5,852.62	8,879.05	4,405.78	26,090.59
	Non-controlling interest	(82.93)	(32.35)	-	(167.68)
	Profit for the period	5,769.69	8,846.70	4,405.78	25,922.91
13	Other comprehensive income for the period attributable to:				
	Owners of the company	1,705.93	1,335.09	(281.88)	5,537.72
	Non-controlling interest	0.21	(8.75)	-	(13.36)
	Other comprehensive income for the period	1,706.14	1,326.33	(281.88)	5,524.36
14	Total comprehensive income for the period attributable to:				
	Owners of the company	7,558.55	10,214.15	4,123.90	31,628.31
	Non-controlling interest	(82.72)	(41.11)	-	(181.04)
	Total comprehensive income for the period	7,475.83	10,173.04	4,123.90	31,447.27
15	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16
16	Other equity				2,00,659.97
17	Earnings per share				
	Basic and diluted (In Rs.) (not annualised for the quarter)	5.52	8.46	4.21	24.78

Refer notes to the unaudited consolidated financial results




CONCORD BIOTECH LIMITED


B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited consolidated financial results for the quarter ended June 30, 2026:


1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on July 31, 2026. The Statutory Auditors of the Holding Company have carried out a limited review of the said results.
2. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2025 which were subjected to limited review.
3. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Group has recognized an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The Group continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
4. The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
5. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").
6. Celliimune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026.



Place: Ahmedabad
Date: July 31, 2026



For and on behalf of board of directors of
Concord Biotech Limited


Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Limited Review Report on unaudited standalone financial results of Concord Biotech Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Concord Biotech Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Concord Biotech Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Co. LLP

Limited Review Report (*Continued*)
Concord Biotech Limited

contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022



Rupen Shah
Partner

Ahmedabad
31 July 2026

Membership No.: 116240
UDIN:26116240TZSCDT1327

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. In lakhs except per share data)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-26 (Unaudited)	31-Mar-26 (Refer Note 2)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
1	Income				
a	Revenue from operations	26,051.71	32,589.20	20,398.76	1,05,507.10
b	Other income	1,309.64	1,554.17	1,367.76	5,273.06
	Total Income	27,361.35	34,143.37	21,766.52	1,10,780.16
2	Expenses				
a	Cost of materials consumed	6,985.45	7,054.09	5,990.99	25,434.78
b	Purchase of stock-in-trade	1,125.96	1,567.01	1,284.63	6,222.86
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,547.18)	(53.57)	(2,765.10)	(7,061.49)
d	Employee benefits expense	4,118.15	4,501.87	3,789.74	17,018.60
e	Finance costs	1.50	5.84	5.86	23.40
f	Depreciation and amortisation expense	1,804.73	1,948.67	1,777.63	7,432.51
g	Other expenses				
	Power and fuel	3,472.01	2,975.97	2,947.50	11,619.93
	Others	4,179.77	4,305.73	3,011.32	14,618.85
	Total expenses	19,140.39	22,305.61	16,042.57	75,309.44
3	Profit before exceptional items and tax (1-2)	8,220.96	11,837.76	5,723.95	35,470.72
4	Exceptional items:				
	Statutory impact of new labour codes (refer note 3)	-	-	-	327.54
5	Profit before tax (3-4)	8,220.96	11,837.76	5,723.95	35,143.18
6	Tax expenses:				
a	Current tax	2,036.59	2,864.81	1,407.85	8,629.09
b	Deferred tax	65.00	(29.26)	59.55	187.42
	Total tax expenses	2,101.59	2,835.55	1,467.40	8,816.51
7	Profit after tax for the period/year (5-6)	6,119.37	9,002.21	4,256.55	26,326.67
8	Other comprehensive income (net of tax)				
	Items that will not be reclassified to profit or loss				
a	Re-measurement gain/ (loss) on defined benefit plans	71.56	(68.75)	(32.07)	(162.24)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	(18.01)	17.30	8.07	40.83
c	Fair value changes on equity investments through OCI	1,927.33	1,685.42	(344.61)	6,687.09
d	Income tax relating to fair value changes on equity investments through OCI	(275.61)	(272.63)	86.73	(987.87)
	Other comprehensive income for the period/year	1,705.27	1,361.34	(281.88)	5,577.81
9	Total comprehensive income for the period/year (7+8)	7,824.64	10,363.55	3,974.67	31,904.48
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16
11	Other equity				2,00,929.01
12	Earnings per share				
	Basic and diluted (In Rs.) (not annualised for the quarter)	5.85	8.60	4.07	25.17

Refer notes to the unaudited standalone financial results

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440


E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited standalone financial results for the quarter ended June 30, 2026:


1. The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on July 31, 2026. The Statutory Auditors of the company have carried out a limited review of the said results.
2. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2025 which were subjected to limited review.
3. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Company has recognized an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The Company continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
4. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
5. The above standalone financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").
6. Celliimune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026.



Place: Ahmedabad
Date: July 31 2026



For and on behalf of board of directors of
Concord Biotech Limited


Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

- A. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. - **Not Applicable**
- B. Format for Disclosing Outstanding Default on Loans and Debt Securities — **Not Applicable, No Default**
- C. Format for Disclosure of Related Party Transactions (applicable only for half yearly filings i.e., 2nd and 4th quarter) — **Not Applicable**
- D. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**